🚀 Exciting news for Parkinson's research: the #EJSACTPD trial has added a third potential treatment, ursodeoxycholic acid (UDCA).
The world's largest trial of treatments to slow Parkinson's disease is now testing more promising therapies, faster.
www.innovative-ctu.ucl.ac.uk/news/news-st...

🚨Big news in Parkinson’s research!

We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.

🔗 More www.mrcctu.ucl.ac.uk/news/news-st...

🎉 Big news from the #EJSACTPD team!

We have 7 abstracts accepted at World PD Congress 2026 🎉

Showcasing our innovative MAMS trial, inclusive recruitment, patient & public involvement and #JoinParkinsonsResearch registry hosted by @ResearchPlusMe 🙌

#WPC2026 @worldpdcongress.bsky.social

The world’s largest-ever clinical trial of treatments to slow or stop the progression of Parkinson’s disease has launched, led by researchers at @uclqsion.bsky.social @uclh.bsky.social and @newcastleuni.bsky.social, accelerating the search for effective treatments in a £26 million project #ejsactpd

#ParkinsonsDisease #Parkinsonstherapies #baskettrial #EJSACTPD #repurposedpharmaceuticals #Parkinsonstreatments #UCL #MRC #NIHR #CureParkinsons #TheMichaelJFoxFoundation #ParkinsonsUK #TheJohnBlackCharitableFoundation #TheGatsbyCharitableFoundation #VanAndelInstitute
zurl.co/EOu6m